dup (11q) in myeloid malignancies by Zamecnikova, Adriana & Al Bahar, Soad
Leukaemia Section 
Short Communication 
Atlas Genet Cytogenet Oncol Haematol. 2017; 21(9) 327 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
INIST-CNRS OPEN ACCESS JOURNAL 
dup (11q) in myeloid malignancies 
Adriana Zamecnikova, Soad Al Bahar 
Kuwait Cancer Control Center, Department of Hematology, Laboratory of Cancer Genetics, Kuwait 
annaadria@yahoo.com 
Published in Atlas Database: November 2016 
Online updated version : http://AtlasGeneticsOncology.org/Anomalies/dup11qMyeloID1629.html 
Printable original version : http://documents.irevues.inist.fr/bitstream/handle/2042/68540/11-2016-dup11qMyeloID1629.pdf 
DOI: 10.4267/2042/68540
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 
© 2017 Atlas of Genetics and Cytogenetics in Oncology and Haematology 
Abstract 
Partial gain of the long arm of chromosome 11, 
containing the unrearranged mixed lineage 
leukaemia (MLL) gene (KMT2A; lysine (K)-
specific methyltransferase 2A) is a rare but recurrent 
anomaly in myeloid malignancies, and is often 
associated with an older age and a higly complex 
karyotype. 
Keywords 
gene amplification, intrachromosomal KMT2A 
duplication,  karyotype complexity, acute myeloid 
leukemia. 
Identity 
A different mode of duplication is the internal partial 
tandem duplication (PTD) of KMT2A (MLL) 
(MLL-PTD), repeating the 5' part of the gene leading 
to its self-fusion. MLL-PTD occurs in approximately 
10% of cytogenetically normal acute myeloid 
leukemias (AML) and in the majority of AML cases 
with trisomy 11 as a sole abnormality. 
Clinics and pathology 
Disease 
Chronic myeloproliferative neoplasms and acute 
myeloid leukemia (AML). 
Phenotype/cell stem origin 
Phenotype / cell stem origin  25 of the 29 cases 
presented were AML, 3 were diagnosed with 
myelodysplasia  (MDS) (Werner et al., 1992; 
Harrison et al., 1998; MacGrogan et al., 2004)  and 
1 with chronic myeloid leukemia (CML) (Pedersen 
et al., 2000). While the most common phenotype of 
AML cases with MLL translocations is AML-
M4/M5, the phenotype of AML cases was AML-M1 
(7 patients) mainly (Soni et al., 1996; Green et 
al.,1999; Cuthbert et al., 2000; Brezinova et al., 
2002; Mrozek et al., 2002; Arnaud et al., 2005; 
Babicka et al., 2007). In addition, there were 1 AML-
M0 (Van Limbergen et al., 2002), 5 AML-M2 (Soni 
et al., 1996; Mauritzson et al., 2002; Van Limbergen 
et al., 2002;  Rucker et al., 2006), 1 AML-M4 
(Harrison et al., 1998), 4 AML-M5 (Kaneko et al., 
1982; Harrison et al., 1998; Xu et al., 2001), 1 AML-
M7 (Dastugue et al., 2002) and 6 AML not specified 
cases (Smadja et al., 1989; Lai et al., 1995; Andersen 
et al., 2005; Babicka et al., 2007; Lessard et al., 
2007;  Huh et al., 2013). Among the 29 patients, 1 
patient developed AML after therapy for multiple 
myeloma (Soni et al., 1996), 2 after therapy for 
adenocarcinoma (Mauritzson et al., 2002; Andersen 
et al., 2005) and 1 after chemotherapy for diffuse 
large B-cell lymphoma (Huh et al., 2013) (Table 1). 
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Légend (A) Partial karyotypes with 11q duplication. (B) Fluorescence in situ hybridization (FISH) with LSI MLL (Vysis/Abott, USA) 





Diagnosis Karyotype  
1 F/0 AML- M5 51,XX,+1,del(1)(p22)x2,+3,+6,+9,add(10)(p13),dup(11)(q11q21),+19/52,idem,+18 
2 F/60  AML 
44,XX,der(1)t(1;4)(q11;p11),+der(1)t(1;7)(p11;p11),-
4,del(5)(q14q34),der(7)t(7;17)(q11;q11),dup(11)(q12q13),-12,-17,-20,+mar  
3 M/84 RAEB 46,XY,dup(11)(q13q25) 
4 M/53 AML 
44-45,XY,-3,-5,-10,dup(11)(q12q13),add(12)(p12),add(14)(q32),der(17)t(5;17)(p11;p11),i(18)(q10), 
+1-2mar 




6 F/83 AML- M2 
44-47,XX,-
5,der(6)t(6;13)(p22;q21),+der(11)ins(11;11)(q24;q?12q14),+dup(11)(q23q25),+i(11)(q10),del(13)(q?)
,der(16)t(13;16)(q?;q?13),del(17)(p?),-18, der(22)t(13;22)(q?;p11) multiple myeloma, chemotherapy  









10 M/63 RA 43,X,-Y,del(5)(q13q33),der(7)t(7;13)(p22;q1?),-9,der(11)add(11)(p15)dup(11)(q14q23),-13 
11  M  AML-M1  43,XY,del(5)(q15q33),-7,-11,dup(11)(q13q23),-17,der(18)t(7;18)(q22;q23)/44, idem,+mar 
12 F/76  AML-M1  45,XX,del(5)(q13q33),del(7)(q?11q36),dup(11)(q23q23),-16,add(16),der(18)t(16;18)(?;p11) 
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12,del(14) (q22),-16,-17,ins(17;1),+der(?)t(?;12)(?;q?), +2mar adenocarcinoma, chemotherapy, 
radiotherapy  




19 F/68 AML- M2 43,XX,-4,del(5)(q12q34),der(10)t(1;10)(p13;q26),dup(11)(q?24q?),-17,-18  




21 M/76 AML- M2 
46,XY,der(1;19)t(1;19)(p13;p12)t(1;19)(p36;q13),der(5)t(5;17)(q13;q11-22), 
dup(11)(q?24q?),der(17)r(5;17) -19,+22,i(22)(q10)x2 
22 M RAEB 
44-
49,XY,+Y,del(1)(q32),add(2)(p25),del(5)(q15q31),der(6)t(2;6)(q21;q13),del(7)(q22),+9,add(9)(q34)x
2, add(11(p13),dup(11)(q13q23),-17,add(17)(p11), add(19)(p13),-20,i(21)(q10),+2mar 




23q23),-12,der(12)t(12;21),der(21)t(12;21) adenocarcinoma, chemotherapy  
24 F/60 AML-M1 46,XX,der(3)t(3;11)(q29;q11)/46,XX,dup(11)(q14q23) 
25 F/64 AML-M2 44,XX,del(2)(q31q35),-4,del(5)(q13q33),-11,dup(11)(q21q23),-14,del(17)(q21),del(18)(q21),+mar 




27 F/66 AML-M1 
46,XX,del(5)(q13q33),del(7)(q21q33),dup(11)(q13q23),-17,der(20)t(17;20)(q12;q11)/46,XX,del(5), 
del(7),+8, dup(11),-14,der(17)t(14;17)(?;q12),der (20)t(17;20)  
28 M/60 AML 
46,XY,del(5)(q13q33),dup(11)(q23q23)/43,idem,-4,-17,-18/42,idem,del(2)(q21),-6,-dup(11), 
add(12)(p11), del(12)(p11),-16,-17,-18 
29 M/63 AML 
42,X,-Y,del(1)(q32),add(2)(q13),-4,add(4)(q31),del(5)(q15q33), add(6)(p25), 
add(6)(q13),der(7;16)(p10;q10), -8,add(10)(p13),dup(11)(q23q25),add(13)(p11),-16,-
17,add(18)(q12),add(20)(q13),+2mar diffuse large B-cell lymphoma, chemotherapy 
Abbreviations: F., female; M., male; AML., acute myeloid leukemia; AML-M5.,  acute monoblastic  leukemia; RAEB., refractory 
anemia with excess of blasts;  AML-M1., acute myeloblastic leukemia without  maturation; AML-M2., acute myeloblastic 
leukemia with maturation; AML-M5a., acute  monoblastic leukemia without differentiation; AML-M4., acute myelomonocytic  
leukemia; AML-M5b., acute monocytic leukemia; RA., refractory anemia; CML., chronic  myeloid leukemia; APL., acute 
promyelocytic leukemia; DS., Down's syndrome; MDS., myelodysplastic syndrome; AML-M0., acute  myeloblastic leukemia with 
minimal differentiation. 
1. Kaneko et al., 1982; 2. Smadja et al., 1989; 3. Werner et al., 1992; 4. Lai et al., 1995; 5-6. Soni et al., 1996; 7-10. Harrison et 
al., 1998; 11. Green et  al.,1999; 12. Cuthbert et al., 2000; 13.  Pedersen et al., 2000; 14. Xu et al.,  2001; 15. Brezinova et al., 
2002; 16. Dastugue  et al., 2002; 17. Mauritzson et al., 2002; 18. Mrozek et al., 2002; 19-21. Van  Limbergen et al., 2002; 22. 
MacGrogan et al., 2004; 23. Andersen et al., 2005; 24.  Arnaud et al., 2005; 25. Rucker et al.,  2006; 26-27. Babicka et al., 2007; 
28. Lessard  et al., 2007; 29. Huh et al., 2013. 
 
Prognosis 
The over-representation of complex karyotypes in 
association with unbalanced rearrangements and/or 
chromosome 5 and 7 anomalies may reflect genomic 
instability and correlate with an unfavorable 
outcome in patients with 11q duplications. 
Epidemiology 
16 male and 13 female patients with median age of 
63 years (range 0 to 86 years), among them 2 were  
infants  (aged 0 and 1 years) and a single  pediatric 
case aged 15 years. The ages of the adult patients 
ranged from 23 to 86 years, with a mean age of 63 
years. 










Fluorescence in situ hybridisation (FISH) allows 
identification of genes included in the amplified 
regions such as duplicated copies of MLL located 
together on the same chromosome arm without gene 
splitting. 
Cytogenetics morphological 
Identified as add(11)(q) with cytogenetically 
heterogeneous breakpoints by conventional 
cytogenetic analysis. The involved region was 
within the 11q13 to 25 bands in the majority of 
patients, clustering within the 11q13 to 23 and 11q23 
to 25 regions and within the 11q11 to 21 bands in 4 
cases. 
Additional anomalies 
Significantly associated with complex karyotypes; 
sole anomaly only in 2 patients:1 with refractory 
anemia with excess of blasts (Werner et al., 1992) 
and 1 AML case (Harrison et al., 1998), associated 
with monosomy 10 in 1 (Harrison et al., 1998,), 
pentasomy 8 in 1 (Harrison et al., 1998) and found in 
an unrelated clone in 1 AML case (Harrison et al., 
1998). Highly complex anomalies in the remaing 
cases including dicentric chromosomes, highly 
rearranged chromosome derivatives and unbalanced 
structural aberrations; loss or deletion of 
chromosome 5 was found in 10 patients (Smadja et 
al., 1989;  Lai et al., 1995;  Soni et al., 1996; Harrison 
et al., 1998; Mauritzson et al., 2002; Van Limbergen 
et al., 2002; Van Limbergen et al., 2002; Rucker et 
al., 2006; Lessard et al., 2007; Huh et al., 2013), 
while simultaneous loss or deletion of chromosomes 
5 and 7 was found in 7 (Green et al.,1999; Cuthbert 
et al., 2000;  Brezinova et al., 2002; Mrozek et al., 
2002; MacGrogan et al., 2004; Babicka et al., 2007; 
Babicka et al., 2007). 
Loss or deletion of chromosomes 5 and 7 was 
accompanied with -17 or 17p rearrangements in 11 
cases (Smadja et al., 1989;  Lai et al., 1995;  Soni et 
al., 1996; Green et al.,1999; Mauritzson et al., 2002; 
Van Limbergen et al., 2002; MacGrogan et al., 2004; 
Babicka et al., 2007; Babicka et al., 2007; Lessard et 
al., 2007; Huh et al., 2013). 




The MLL gene, located at 11q23, is frequently 
rearranged in acute leukaemia as either gene fusions 
or partial tandem duplications, but 11q duplication is 
a relatively rare anomaly in myeloid malignancies. 
In the majority of cases it is found as a part of a 
highly complex karyotype representing clonal 
evolution that plays a role in disease progression. 
Chromosome dupplications occurs in a broad 
spectrum of malignancies and typically leads to 
inappropriate activation or overexpression of one or 
more oncogenes located within the amplicon. FISH 
and expression analyses confirmed MLL as a 
prominent target within 11q23 copy gain or 
amplification, providing further evidence for an 
etiologic role for MLL gain of function in myeloid 
malignancies. However, as varying and often large 
parts of 11q are involved in chromosome 
duplication, it is possibile that gains of other genes 
such as DDX6, ETS1, and FLI1 may contribute to 
leukemogenesis as a gain-of-function mutation 
(Pope et al., 2004). 
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